Promising ALS drug MCI-186 put to the test in major trial
NCT ID NCT00330681
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 14 times
Summary
This study tested whether a drug called MCI-186 can slow the progression of ALS, a serious nerve disease that weakens muscles over time. About 200 people with ALS received either the drug or a placebo daily for 24 weeks. Researchers measured changes in physical function to see if the drug helped maintain abilities like walking and breathing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.